The US Albumin Market is projected to experience continued expansion as demand for albumin increases across therapeutic, pharmaceutical, biotechnology, diagnostic, and research applications. Market Research Future reports that the market is expected to grow from USD 224.92 million in 2025 to USD 420 million by 2035 at a CAGR of 6.44%.

Increasing chronic disease prevalence is a major factor supporting market growth. Albumin has important applications in the treatment and management of conditions such as liver disease and burn-related medical situations. The expanding healthcare infrastructure in the United States is also helping improve access to albumin-based therapies.

Technological advancement represents another important growth driver. Innovations in recombinant DNA technology and purification processes are supporting the development of high-quality albumin products. Recombinant albumin is expected to be one of the fastest-growing source categories as biotechnology capabilities advance.

The market also faces challenges, including regulatory requirements, manufacturing complexity, supply-chain considerations, and the need for high-quality raw materials. Maintaining product safety and consistency remains particularly important for therapeutic albumin applications.

Despite these challenges, significant opportunities exist in albumin-based drug delivery, specialized pharmaceutical formulations, biotechnology research, and automated manufacturing technologies. The increasing use of albumin in biopharmaceutical development may further expand its commercial applications.

Hospitals are expected to remain the leading end users, while diagnostic laboratories and pharmaceutical companies may contribute increasingly to market expansion.

Overall, innovation, healthcare investment, advanced manufacturing, and growing therapeutic demand are expected to shape the future of the US Albumin Market.